WHAT IS VIBAZIN USED FOR? - MEDICINE - 2024

The vibazina used to treat nausea, vomiting and dizziness associated with disorders in the vestibular system. Vibazin is the trade name for buclizine hydrochloride distributed by the Pfizer laboratory (Pfizer, 2016).

After falling into disuse for several years, the use of vibazin has become popular again thanks to various campaigns run by drug laboratories that distribute buclizine hydrochloride.

Currently vibazin is promoted primarily as an appetite stimulant for underweight individuals, an antihistamine, and an antiemetic.

As an antiemetic, vibazin reduces dizziness and nausea, regulating the functions of the vestibular system. As an antihistamine, this drug reduces allergies, it has also been shown to be successful as an analgesic in treating migraines, insomnia and some types of diabetes.

Vibazin syrup is marketed as an appetite stimulant especially for children with nutritional deficiencies. Although its potential as an appetite stimulant has always been promulgated, only during the last twenty years have laboratories decided to promote this drug with scientific supports, proving its efficacy.

Despite the fact that vibazin is marketed primarily as an appetite stimulant, there is no current study on these qualities of the drug.

Similarly, no scientific article has been published on vibazin for more than twenty years, and no pharmacological information has been found to indicate that buclizine hydrochloride is an appetite stimulant.

Uses of buclizine or vibazin hydrochloride

Buclizine hydrochloride is a salt derived from piperazine used primarily as an anti-vertigo and antiemetic. Buclazine is used primarily in the prevention and treatment of nausea, vomiting, and discomfort related to disorders of the vestibular system (Gaillard, 1955).

The full uses of buclizine hydrochloride have not yet been fully elucidated, however, the anticholinergic effects of buclazine as an impulse blocker directed to the parasympathetic system through the nerves have been evidenced in different studies.

This drug is also widely used as an antihistamine, a central nervous system suppressant, and a local anesthetic (Settel, 1959). Some of the most commonly seen effects in patients taking buclizine hydrochloride include the following:

• Decreased vestibular stimulation: vibazin has been found to have an effect in reducing stimuli to the vestibular system, which contributes to the maintenance of balance and prevents the patient from feeling dizzy or discomfort caused by movement
• Reduction in labyrinthine functions: vibazin-treated patients are less likely to experience dizziness or balance problems caused when labyrinthine functions fail.

Vibazin essentially serves as an ideal medication to reduce overstimulation of the vestibular apparatus that sends signals to the vomiting center located in the medullary part of the brain.

Disorders in the vestibular system generally produce emesis or vomiting, and vibazin serves to reduce physiological activities that send stimuli to receptors located in the center of vomiting (Association, 1992).

Vibazin as an appetite stimulant

Vibazin is originally an antihistamine that has been widely used as an antiemetic for decades and even as an analgesic in the treatment of migraines. However, it is also used as an appetite stimulant comparable to Cyproheptadine.

Vibazin serves to improve the absorption of food in the body without affecting the hormonal levels of the same. This means that in pregnant patients, vibazin would not affect embryonic development or the production of hormones necessary for gestation (FJ & NESBITT, 1958).

Unlike other appetite stimulants, once vibazin consumption is discontinued, the weight gained during its use tends to remain (Pharmacol, 2011).

Recommended dose

For the effects of vibazin in adults to be visible, it is recommended to consume 50 to 150 mg of buclizine hydrochloride daily divided into three doses. The amount to be administered in infants must be determined by the judgment of the treating physician.

It is important to avoid consuming more than the amount prescribed by your doctor. This in order to avoid poisoning and other harmful effects to the body caused by possible poisoning.

In the event that such poisoning occurs, the patient should go to the nearest hospital with the vibazin packaging so that the treating physician can analyze the drug.

Similarly, it should be clarified that for the vibazin to fulfill its functions it must be in perfect condition, kept in a dry and cool space, away from direct light or high temperatures.

Side effects of vibazin

Despite the many uses of vibazin, its consumption can cause some side effects. These effects may appear, however, they do not always affect patients treated with this drug (Drugs.com, 1996). Patients who notice any of the following side effects should consult their doctor:

1. Blurry vision
2. Dry mouth, nose, and throat
3. Headache
4. Nervousness and anxiety
5. Exhaustion
6. Diarrhea
7. Constipation
8. Palpitations
9. Gastric pain
10. Fluid retention

Precautions

Vibazin is a rapidly absorbed oral drug. It is recommended to take some precautions in its consumption because some health conditions of certain patients can lead them to have hypersensitivity to the drug and the appearance of side effects.

On the other hand, once the consumption of buclizine hydrochloride begins, patients must be constant with its intake, otherwise the effects of the medication will not be visible.

It is recommended to locate the vibazin in a visible place where it is passed every day, such as the kitchen or the bathroom, this will avoid forgetting its consumption. The use of alarms as reminders to take vibazin is also recommended.

It is important to note that vibazin is a drug that is metabolized by the liver and that the intake of alcohol or other suppressants of the central nervous system can affect the motor functions of the body by intensifying the effects of vibazin.

References

1. Association, AM (1992). Drug evaluations subscription, 414.
2. com. (3 of 1 of 1996). Drugs.com. Retrieved from Buclizine (Systemic): drugs.com
3. FJ, C., & NESBITT, ER (1958). Buclizine Hydrochloride for Nausea and Vomiting of Pregnancy. Obstetrics & Gynecology, Volume 11 - Issue 2, 214-219.
4. Gaillard, G. (1955). Clinical evaluation of a new antihistamine, buclizine hydrochloride (Vibazine). Journal of Allergy, Volume 26, Issue 4, 373-376.
5. Pfizer, L. (1 of 04 of 2016). My Vademecum. Obtained from Vivazina - Pfizer Laboratory: mivademecum.com.
6. Pharmacol, IJ (4 of 2011). US National Library of Medicine. Obtained from Buclizine is back again! This time as a pediatric appetite stimulant: ncbi.nlm.nih.gov.
7. Settel, E. (1959). Buclizine, A New Tranquilizing Agent. Journal of The American Geriatrics Society, 67.